Trademark: 97542778
Word
PROGNOSTXHEALTH
Status
Pending
Status Code
688
Status Date
Tuesday, January 16, 2024
Serial Number
97542778
Mark Type
4000
Filing Date
Wednesday, August 10, 2022
Published for Opposition
Tuesday, November 21, 2023

Trademark Owner History
AmDx PrognostX, Inc. - Owner At Publication

Classifications
9 Computer hardware, recorded software, and control algorithms sold as a unit for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers including cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder
5 diagnostic kits and instruments primarily comprised of immunological assays, antibodies and reagents for medical testing of diseases; testing apparatus and instruments being diagnostic kits for medical or research purposes primarily comprised of reagents for creating assays to capture and detect disease biomarkers
44 Medical diagnostic services relating to diseases; medical testing services relating to the diagnosis and treatment of disease; Medical services, namely, administering reagent-based sample tests for others for diagnosis of diseases; Providing medical diagnostic information services for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers, cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder using computers, software and algorithms
10 diagnostic kits and instruments primarily comprised of a coated surface, a reagent and an immunoassay using antibodies or molecular probes for medical diagnosis of diseases and medical use; testing apparatus and instruments for medical purposes in the nature of a coated plate or other surface materials including but not limited to plastic, glass, or metals used to create assays to capture and detect disease biomarkers; Medical diagnostic and therapeutic apparatuses primarily comprised of antibody or antigen coated surfaces, reagents, immunoassays, computers, software and algorithms for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers including cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder
42 Biomedical research services; scientific laboratory services; providing reagent sample testing for others in the fields of medical diseases and medicine; Development of testing for kidney diseases in a laboratory setting; Medical and scientific research, namely, conducting clinical trials for others featuring clinical trial design, statistical evaluation, and execution; Scientific and medical research and consulting services featuring algorithms, artificial intelligence and machine learning development, evaluation and clinical utility; Scientific and medical research and consulting services featuring biostatistical support; Manufacturing services, namely, development of minimal viable products in the nature of medical diagnostic tests for others; consulting services related to laboratory developed testing procedures, strategy and execution in the field of medical diagnostics, medical tests and pharmaceutical research; Quality evaluation of clinical utility and applicability of innovative technologies in the medical field

Trademark Events
Jan 16, 2024
Noa E-Mailed - Sou Required From Applicant
Dec 5, 2023
Assigned To Examiner
Nov 21, 2023
Official Gazette Publication Confirmation E-Mailed
Nov 21, 2023
Published For Opposition
Nov 1, 2023
Notification Of Notice Of Publication E-Mailed
Oct 13, 2023
Approved For Pub - Principal Register
Oct 13, 2023
Examiner's Amendment Entered
Oct 13, 2023
Notification Of Examiners Amendment E-Mailed
Oct 13, 2023
Examiners Amendment E-Mailed
Oct 13, 2023
Examiners Amendment -Written
Sep 7, 2023
Teas/Email Correspondence Entered
Sep 6, 2023
Correspondence Received In Law Office
Sep 6, 2023
Teas Response To Office Action Received
Jun 8, 2023
Notification Of Non-Final Action E-Mailed
Jun 8, 2023
Non-Final Action E-Mailed
Jun 8, 2023
Non-Final Action Written
May 30, 2023
Assigned To Examiner
Aug 30, 2022
New Application Office Supplied Data Entered
Aug 13, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24